×

Celebrating 15 Years of Excellence

Find Out More >
Celebrating 15 Years of Excellence

CFDs and Spread Bets are complex instruments and come with a high risk of losing money rapidly due to leverage. 67.9% of retail investor accounts lose money when trading CFDs and Spread Bets with this provider. You should consider whether you understand how CFDs and Spread Bets work and whether you can afford to take the high risk of losing your money.

Risk Disclosure Notice
  • Vantage 15Vantage 15 Years
  • Institutional

  • LiveREGISTER

  • en
  • Search
View More
SEARCH
  • All
    Trading
    Platforms
    Academy
    Analysis
    Promotions
    About
  • Search query too short. Please enter a full word or phrase.
  • Search
Keywords
Popular Search

Access Restricted

Your access to this website is restricted.

Our website and services are not available to, and are not intended for, individuals who are citizens or residents of the United States, or entities incorporated in or conducting business within the United States.

If this does not apply to you and you believe you have received this message in error, please contact us at support@vantagemarkets.com for further assistance.

If you fall into any of the above categories, please exit the site.

  • facebook
  • instagram
  • twitter
  • linkedin
HomeRight Arrow NotificationsRight Arrow Product UpdatesRight Arrow Delisting of ABIOMED Inc (ABMD) on 23 December 2022

Back

Notifications 23 Dec 2022

Delisting of ABIOMED Inc (ABMD) on 23 December 2022

NOTIFICATIONS

Please be advised that due to the acquisition by Johnson & Johnson, ABIOMED Inc (ABMD) will be delisted.

This will take place as per the following schedule:

  • Effective Date: 23 December 2022

Due to this corporate action event, only the closing of current ABIOMED Inc (ABMD) positions will be made available.

What happened to ABIOMED Inc (ABMD)?

ABIOMED Inc. on 22 December 2022 announced the completion of its acquisition by Johnson & Johnson (NYSE:JNJ). Johnson & Johnson’s tender offer comprises an upfront payment of $380 per share in cash. ABIOMED is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment

For the full press release, please refer here.

If you have any questions, or require assistance, please do not hesitate to contact support@vantagemarkets.co.uk.

IN CASE YOU MISSED IT